If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

19 Dec 2014 07:00

RNS Number : 2485A
Fastnet Oil & Gas PLC
18 December 2014
 



19 December 2014

Fastnet Oil & Gas plc

("Fastnet", the "Company" or the "Group")

 

Interim Results for the six months ended 30 September 2014

 

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focussed on near-term exploration and appraisal acreage in Morocco and the Celtic Sea, announces its interim results for the six month period ended 30 September 2014.

 

Operational Highlights

· Foum Assaka farm-out to SK Innovation completed in April 2014 for back costs and a carried interest in the FA-1 well and a potential carried interest in a second well

· FA-1 well completed in May 2014 having encountered live oil shows and provided supporting evidence for reservoir development. Post-well technical studies are ongoing to incorporate all of the FA-1 well data into the geological framework of the Foum Assaka Licence

· Celtic Sea and Tendrara Lakbir farm-out processes commenced and ongoing with the Company working towards bringing in partners to further pursue exploration activities

· Improved terms and option extension secured on Tendrara Lakbir in June 2014 and on Deep Kinsale in August 2014

 

Financial and Corporate Highlights

· US$18.8m cash balance at 30 September 2014 (US$17.4m at 31 March 2014, US$10.9m at 30 September 2013) with no material outstanding licence commitments

· US$20.4m in backs costs received from SK Innovation on completion of the Foum Assaka farm-out

· Net loss for the period of US$1.6m which reflects the increase in technical work developing Fastnet's portfolio during the period (6 months to 31 March 2014: loss of US$1.7m, 6 months to 30 September 2013: loss of US$0.9m). The current period net loss comprises general and administrative costs of US$1.6m, a share-based payment charge of US$0.1m and finance income of US$0.1m. Ongoing monthly general and administrative costs in 2015 forecast to reduce from US$275k to US$215k per month

· Carol Law appointed Chief Executive Officer in December 2014 and Will Holland appointed to the Board as Chief Financial Officer in May 2014

 

 

Carol Law, CEO of Fastnet, commented:

 

"Throughout 2014, Fastnet continued its strategy of monetising the Company's existing assets and prudently managing its significant cash reserves in order to create shareholder value. The Foum Assaka farmout was a prime example of this strategy with the FA-1 well delivered at a cost of just US$2.75m to the Company. As the technical studies progress we look forward to continue working with Kosmos, BP and SK in evaluating the licence potential and, in the event of drilling a second well on the licence, the Company would have a further carried interest.

"The oil and gas sector is faced with challenging times but looking ahead to 2015, we believe that Fastnet's portfolio will increase in marketability as industry focus moves towards profitable shallow water and onshore projects in attractive fiscal regimes with low operating costs. In this regard, we will continue to work towards bringing in partners to further pursue exploration activities across our portfolio and seek appropriate licence extensions to enable us to execute this strategy.

"Fastnet is well positioned as a result of a strong balance sheet, management team and asset portfolio. Prudent management will deliver a significant reduction in ongoing general and administrative costs going forward and we will continue to develop and grow the asset portfolio in a selective and low-cost manner as is possible."

A copy of the interim report is now available for download via the following link: http://www.fastnetoilandgas.com/investor-relations/reports/financial-reports/2014.aspx

 

 

For further information please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Non-Executive Chairman

Carol Law, Chief Executive Officer

Will Holland, Chief Financial Officer

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

 

+44 (0) 20 7408 4090

GMP Securities Europe LLP

(Joint Broker)

Rob Collins, Emily Morris, Liz Williamson

 

+44 (20) 7467 2800

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

 

+353 (1) 679 6363

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, Jimmy Lea

 

+44 (0) 203 772 2500

 

 

  

Consolidated Statement of Comprehensive Income

For the six months ended 30 September 2014

 

Unaudited

Unaudited

Audited

6 months to

 30 September 2014

6 months to

 30 September 2013

12 months to 31 March

 2014

US$'000

US$'000

US$'000

Continuing operations

Revenue

-

-

-

Operational costs

-

-

-

Gross loss

-

-

-

General and administrative costs

(1,651)

(913)

(2,469)

Share based payments

(74)

(233)

(464)

Operating loss

(1,725)

(1,146)

(2,933)

Finance revenue

95

125

201

Net foreign exchange gain

2

165

175

Loss on ordinary activities before taxation

(1,628)

(856)

(2,557)

Tax on loss on ordinary activities

-

-

-

Loss and total comprehensive loss for the period attributable to the equity holders of the Company

(1,628)

(856)

(2,557)

 

Loss per share:

Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (cent)

 

(0.47)

 

(0.31)

 

(0.87)

 

Consolidated Statement of Financial Position

As at 30 September 2014

 

 

 

Unaudited

30 September 2014

Unaudited

30 September 2013

Audited

31 March

 2014

US$'000

US$'000

US$'000

Assets

Non-current assets

Property, plant and equipment

11

20

14

Exploration and evaluation assets

35,986

32,325

51,644

Total non-current assets

35,997

32,345

51,658

Current assets

Trade and other receivables

148

108

76

Cash and cash equivalents

18,827

10,857

17,428

Total current assets

18,975

10,965

17,504

Total assets

54,972

43,310

69,162

Equity and liabilities

Equity attributable to owners of the parent

Share capital

20,261

15,832

20,261

Share premium

38,918

28,595

38,918

Other reserves

1,996

1,218

1,815

Retained deficit

(6,679)

(3,350)

(5,051)

Total equity

54,496

42,295

55,943

Non-current liabilities

Liability for share based payments

2

166

79

Total non-current liabilities

2

166

79

Current liabilities

Trade and other payables

474

849

13,140

Total current liabilities

474

849

13,140

Total liabilities

476

1,015

13,219

Total equity and liabilities

54,972

43,310

69,162

 

 

  

 

 

 

 

 

Consolidated Statement of Cash Flows

For the six months ended 30 September 2014

 

 

Unaudited

Unaudited

Audited

6 months to

30 September 2014

6 months to

30 September 2013

12 months to 31 March

 2014

US$'000

US$'000

US$'000

Cash flows from operating activities

Group operating loss for the period

(1,725)

(1,146)

(2,933)

Depreciation

3

-

6

Share based payment expense

74

233

464

Movements in working capital:

(Increase)/decrease in trade and other receivables

(72)

3

36

(Decrease)/increase in trade and other payables

(393)

(117)

359

Net cash flow from operating activities

(2,113)

(1,027)

(2,068)

Cash flow from investing activities

Payments for property, plant and equipment

(1)

(7)

(7)

Expenditure on exploration and evaluation assets

(16,994)

(19,937)

(27,382)

Farm-out funds received

20,410

-

-

Bank interest received

95

125

201

Net cash flow from investing activities

3,510

(19,819)

(27,188)

 

Cash flow from financing activities

Net proceeds from issue of equity instruments

-

-

14,971

Net cash flow from financing activities

-

-

14,971

 

Exchange and other movements

2

165

175

 

Net change in cash and cash equivalents

1,399

(20,681)

(14,110)

Cash and cash equivalents at beginning of period/year

17,428

31,538

31,538

Cash and cash equivalents at end of period/year

18,827

10,857

17,428

 

 

Consolidated Statement of Changes in Equity

For the six months ended 30 September 2014

 

 

 

 

Share

capital

 

 

 

Share premium

 

 

Share based payment reserve

 

 

 

Merger reserve

 

Reverse asset acquisition reserve

 

 

 

Capital reserve

 

 

 

Retained deficit

 

 

 

 

Total

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

Balance at 1 April 2013

15,832

28,595

695

11,478

(11,256)

9

(2,494)

42,859

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(856)

(856)

Share based payments

-

-

292

-

-

-

-

292

Balance at 30 September 2013 (Unaudited)

15,832

28,595

987

11,478

(11,256)

9

(3,350)

42,295

 

Balance at 1 October 2013

15,832

28,595

987

11,478

(11,256)

9

(3,350)

42,295

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,701)

(1,701)

Share based payments

-

-

597

-

-

-

-

597

Issue of share capital

4,429

10,323

-

-

-

-

-

14,752

Balance at 31 March 2014

(Audited)

20,261

38,918

1,584

11,478

(11,256)

9

(5,051)

55,943

 

Balance at 1 April 2014

20,261

38,918

1,584

11,478

(11,256)

9

(5,051)

55,943

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,628)

(1,628)

Share based payments

-

-

181

-

-

-

-

181

Balance at 30 September 2014 (Unaudited)

20,261

38,918

1,765

11,478

(11,256)

9

(6,679)

54,496

 

 

 

 

 

1. General Information

Fastnet Oil & Gas plc ("Fastnet" or the "Company") is a company incorporated in England and Wales. Details of the registered office, the officers and advisers to the Company are presented on the Company Information page at the end of this report. The Company is listed on the AIM market of the London Stock Exchange (ticker: FAST) and the Enterprise Securities Market of the Irish Stock Exchange (ticker: FOI).

 

The principal activity of the Company is oil and gas exploration.

 

The interim results of the Company for the six month period ended 30 September 2014 comprise the Company and its subsidiaries (together the "Group").

 

2. Basis of Preparation

The interim results have been prepared on the basis of the recognition and measurement requirements of International Financial Reporting Standards ("IFRS") as adopted by the European Union ("EU"), and their interpretations adopted by the International Accounting Standards Board ("IASB"). As is permitted by the AIM rules the Directors have not adopted the requirements of IAS34 "Interim Financial Reporting" in preparing the financial statements. Accordingly the financial statements are not in full compliance with IFRS and have neither been audited nor reviewed pursuant to guidance issued by the Auditing Practises Board. The accounting policies used in the preparation of the interim financial information are the same as those used in the Company's audited financial statements for the year ended 31 March 2014 and are expected to be used in the 31 March 2015 year-end financial statements.

 

The financial information for the six months ended 31 September 2013 and 31 September 2014 is unaudited. The financial information presented for the year ended 31March 2013 is an extraction from the Group's audited accounts and therefore do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 on which the auditors issued an unqualified report The auditor's report also did not contain a statement under Section 498(2) or 498 (3) of the Companies Act 2006 and did not include reference to any matters the auditor drew attention by way of emphasis. The accounts for the year ended 31 March 2014 have been delivered to the Registrar of Companies. The Directors consider that the financial information presented in this Interim Report represents fairly the financial position, operations and cash flows for the period, in conformity with IFRS. The Interim Report for the six months ended 30 September 2014 was approved by the Directors on 19 December 2014.

 

Presentation of Balances

The Financial Statements are presented in US Dollars ("US$") which is the functional and presentational currency of the Company and the functional currency of all the Group's subsidiary companies. Balances in the Financial Statements are rounded to the nearest thousand (US$'000) except where otherwise indicated.

 

3. Exploration and Evaluation Assets

Offshore Morocco

Onshore Morocco

Offshore Ireland

 

Total

US$'000

US$'000

US$'000

US$'000

Cost

 

 

 

 

At 1 April 2013

9,496

-

2,545

12,041

Additions

1,828

473

17,983

20,284

At 30 September 2013

11,324

473

20,528

32,325

Carrying value 30 September 2013 (unaudited)

11,324

473

20,528

32,325

Cost

 

 

 

 

At 1 October 2013

11,324

473

20,528

32,325

Additions

17,491

505

1,323

19,319

At 31 March 2014

28,815

978

21,851

51,644

Carrying value 31 March 2014 (audited)

28,815

978

21,851

51,644

Cost

 

 

 

 

At 1 April 2014

28,815

978

21,851

51,644

Additions

3,417

751

584

4,752

Proceeds from farm-out

(20,410)

-

-

(20,410)

At 30 September 2014

11,822

1,729

22,435

35,986

Carrying value 30 September 2014 (unaudited)

11,822

1,729

22,435

35,986

 

Completion of farm-out to SK Innovation Co. Ltd.

On 18 December 2013 Fastnet entered into a farm-out agreement with SK Innovation Co. Ltd. ("SK"). Under the terms of the agreement, Fastnet will receive up to a two well carry comprised of a carry in the first exploration well (FA-1) on the Eagle-1 Prospect and first appraisal well (capped at US$100m per well) or at SK's sole discretion a carry in a second exploration well (capped at US$100m) for a 9.375% participating interest (12.5% paying interest) in the Foum Assaka Licence Area. All completion conditions in relation to the farm-out were finalised in April 2014 with Fastnet receiving US$20.4m in back costs from SK on completion.

 

4. Loss per Share - Basic and Diluted

The Group presents basic and diluted loss per share ("LPS") data for its Ordinary Shares. Basic LPS is calculated by dividing the profit or loss attributable to Ordinary Shareholders of the Company by the weighted average number of Ordinary Shares outstanding during the period. Diluted LPS is determined by adjusting the profit or loss attributable to Ordinary Shareholders and the weighted average number of Ordinary Shares outstanding for the effects of all dilutive potential Ordinary Shares, which comprise warrants and share options granted by the Company.

 

The calculation of loss per share is based on the following:

 

6 months to 30 September 2014

6 months to 30 September 2013

12 months to 31 March 2014

Loss after tax attributable to equity holders of the parent (US$'000)

(1,628)

(856)

(2,557)

Weighted average number of Ordinary Shares in issue

345,369,071

273,940,493

294,292,745

Fully diluted average number of Ordinary Shares in issue

345,369,071

273,940,493

294,292,745

Basic and diluted loss per share (cent)

(0.47)

(0.31)

(0.87)

 

Where a loss has occurred, basic and diluted LPS are the same because the outstanding share options and warrants are anti-dilutive. Accordingly, diluted LPS equals the basic LPS.

 

The share options and warrants outstanding as at 30 September 2014 totalled 25,397,423 (31 March 2014: 17,647,423, 30 September 2013: 15,345,628) and are potentially dilutive.

 

5. Subsequent Events

Appointment of Chief Executive Officer

On the 10 December 2014 the Company announced the appointment of Carol Law as Chief Executive Officer of the Company.

 

Termination of Royalty Agreement

On the 10 December 2014 the Company announced that the Royalty Agreement in relation to the Foum Assaka licence area between Pan Maghreb Oil and Gas Limited and Pathfinder Hydrocarbon Ventures Limited, a 100% owned subsidiary of Fastnet has now been terminated.

 

6. Copy of the Interim Report

Copies of the Interim Report are available to download from the Company's website at

www.fastnetoilandgas.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR QKFDNCBDDNBD
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.